We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+44.75%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$89.5M
Cap. Flow
+$53.8M
Cap. Flow %
30.68%
Top 10 Hldgs %
49.35%
Holding
76
New
27
Increased
18
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$13.2M
2
PRTA icon
Prothena Corp
PRTA
+$7.5M
3
AZN icon
AstraZeneca
AZN
+$7.03M
4
QDEL icon
QuidelOrtho
QDEL
+$4.84M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$4.69M

Top Sells

Rank Stock Value
1
GRFS
Grifois
GRFS
+$7.79M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$6.86M
3
ZYXI
Zynex
ZYXI
+$3.17M
4
AGN
Allergan plc
AGN
+$2.59M
5
UNH icon
UnitedHealth
UNH
+$1.97M

Sector Composition

Rank Sector Weight
1 Healthcare 89.33%
2 Real Estate 0.86%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
51
Biogen
BIIB
$30.9B
$615K 0.35%
2,300
-700
-23% -$210K
ENTA icon
52
Enanta Pharmaceuticals
ENTA
$388M
$577K 0.33%
11,500
+900
+8% +$46.6K
CSTL icon
53
Castle Biosciences
CSTL
$955M
$565K 0.32%
+15,000
New +$513K
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$512K 0.29%
3,089
-44,004
-93% -$6.86M
INSP icon
55
Inspire Medical Systems
INSP
$1.73B
$488K 0.28%
+5,608
New +$431K
RAPT
56
DELISTED
RAPT Therapeutics
RAPT
$438K 0.25%
+1,888
New +$292K
LRMR icon
57
Larimar Therapeutics
LRMR
$428M
$400K 0.23%
31,170
-81,197
-72% -$946K
RLMD icon
58
Relmada Therapeutics
RLMD
$566M
$308K 0.18%
6,900
-4,100
-37% -$173K
ARVN icon
59
Arvinas
ARVN
$548M
$201K 0.11%
+6,000
New +$255K
AMRN
60
Amarin Corp
AMRN
$299M
– –
-4,500
Closed -$360K
AYTU icon
61
AYTU BioPharma
AYTU
$24.1M
– –
-698
Closed -$209K
CTSO icon
62
Cytosorbents Corp
CTSO
$24.2M
– –
-69,600
Closed -$538K
ESTA icon
63
Establishment Labs
ESTA
$2.72B
– –
-63,254
Closed -$914K
GRFS
64
Grifois
GRFS
$5.4B
– –
-387,035
Closed -$7.79M
PTCT icon
65
PTC Therapeutics
PTCT
$5.76B
– –
-16,300
Closed -$727K
SNDX icon
66
Syndax Pharmaceuticals
SNDX
$1.75B
– –
-20,980
Closed -$230K
TPST icon
67
Tempest Therapeutics
TPST
$14.5M
– –
-756
Closed -$778K
UNH icon
68
UnitedHealth
UNH
$374B
– –
-7,900
Closed -$1.97M
VNDA icon
69
Vanda Pharmaceuticals
VNDA
$307M
– –
-19,000
Closed -$197K
SWAV
70
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-12,185
Closed -$404K
KDNY
71
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-16,240
Closed -$222K
TCRR
72
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-30,624
Closed -$237K
LVGO
73
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-18,100
Closed -$516K
AGN
74
DELISTED
Allergan plc
AGN
– –
-14,600
Closed -$2.59M
1 2
3

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Soleus Capital Management held 76 positions worth $175M, up 104% from $85.9M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management deployed $53.8M of net new capital in Q2 2020, opening 27 new positions and adding to 18 existing holdings. Its largest new stake was Prothena Corp: 674,603 shares worth $7.06M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 98% a quarter earlier, followed by Real Estate and Communication Services.

On the sell side, the largest reduction was Harpoon Therapeutics, Inc. Common Stock, an estimated $6.86M trimmed.

  • Soleus Capital Management's largest Q2 2020 buy was Prothena Corp: 674,603 shares worth $7.06M.
  • Soleus Capital Management added most to Zymeworks in Q2 2020, an estimated $13.2M increase.
  • Soleus Capital Management's biggest Q2 2020 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $6.86M.
  • Soleus Capital Management fully exited Grifois in Q2 2020, selling an estimated $7.79M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $175M portfolio in Q2 2020.
  • Soleus Capital Management opened 27 new positions and closed 15 in Q2 2020.
  • Soleus Capital Management's portfolio value rose 104% quarter-over-quarter to $175M.

Based on Soleus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.